ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer : pathology and molecular biology and early, advanced and recurrent disease
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Ledermann, J AMatias-Guiu, X
Amant, F
Concin, N
Davidson, B
Fotopoulou, C
González-Martin, A
Gourley, C
Leary, A
Lorusso, D
Banerjee, S
Chiva, L
Cibula, D
Colombo, N
Croce, S
Eriksson, A G
Falandry, C
Fischerova, D
Harter, P
Joly, F
Lazaro, C
Lok, C
Mahner, S
Marmé, F
Marth, C
McCluggage, W G
McNeish, I A
Morice, P
Nicum, S
Oaknin, A
Pérez-Fidalgo, J A
Pignata, S
Ramirez, P T
Ray-Coquard, I
Romero, I
Scambia, G
Sehouli, J
Shapira-Frommer, R
Sundar, Sudha

Tan, D S P
Taskiran, C
van Driel, W J
Vergote, I
Planchamp, F
Sessa, C
Fagotti, A
Affiliation
University College London; Hospital Universitari Arnau de Vilanova; University Hospitals Leuven; Sandwell and West Birmingham NHS Trust; et al.Publication date
2024-01-29Subject
Oncology. Pathology.
Metadata
Show full item recordAbstract
The European Society of Gynaecological Oncology, the European Society for Medical Oncology (ESMO) and the European Society of Pathology held a consensus conference (CC) on ovarian cancer on 15-16 June 2022 in Valencia, Spain. The CC panel included 44 experts in the management of ovarian cancer and pathology, an ESMO scientific advisor and a methodologist. The aim was to discuss new or contentious topics and develop recommendations to improve and harmonise the management of patients with ovarian cancer. Eighteen questions were identified for discussion under four main topics: (i) pathology and molecular biology, (ii) early-stage disease and pelvic mass in pregnancy, (iii) advanced stage (including older/frail patients) and (iv) recurrent disease. The panel was divided into four working groups (WGs) to each address questions relating to one of the four topics outlined above, based on their expertise. Relevant scientific literature was reviewed in advance. Recommendations were developed by the WGs and then presented to the entire panel for further discussion and amendment before voting. This manuscript focuses on the recommendation statements that reached a consensus, their voting results and a summary of evidence supporting each recommendation.Citation
Ledermann JA, Matias-Guiu X, Amant F, Concin N, Davidson B, Fotopoulou C, González-Martin A, Gourley C, Leary A, Lorusso D, Banerjee S, Chiva L, Cibula D, Colombo N, Croce S, Eriksson AG, Falandry C, Fischerova D, Harter P, Joly F, Lazaro C, Lok C, Mahner S, Marmé F, Marth C, McCluggage WG, McNeish IA, Morice P, Nicum S, Oaknin A, Pérez-Fidalgo JA, Pignata S, Ramirez PT, Ray-Coquard I, Romero I, Scambia G, Sehouli J, Shapira-Frommer R, Sundar S, Tan DSP, Taskiran C, van Driel WJ, Vergote I, Planchamp F, Sessa C, Fagotti A. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.11.015Type
ArticlePMID
38307807Journal
Annals of OncologyPublisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2023.11.015